[Pathogenesis of essential hypertension with special reference to therapy].
D000293:Adolescent; D000311:Adrenal Glands / Q000503:physiopathology; D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000627:therapeutic use; D001794:Blood Pressure; D001810:Blood Volume; D003975:Diazepam / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006145:Guanethidine / Q000627:therapeutic use; D006584:Hexamethonium Compounds / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D006977:Hypertension, Renal / Q000503:physiopathology; D008297:Male; D008464:Mecamylamine / Q000627:therapeutic use; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D008517:Phytotherapy; D010946:Plants, Medicinal; D011602:Psychophysiologic Disorders / Q000150:complications; D011926:Rauwolfia / Q000627:therapeutic use; D012890:Sleep; D013997:Time Factors; D014655:Vascular Resistance
D004232:Diuretics; D006584:Hexamethonium Compounds; D000804:Angiotensin II; D008750:Methyldopa; D008464:Mecamylamine; D003975:Diazepam; D006145:Guanethidine
Pathogenese der essentiellen Hypertonie mit spezieller Hinsicht zur Therapie.